PAVmed Inc. reported Q2 2026 results highlighting progress across its subsidiaries: Veris Health advanced commercial engagement and development of an implantable physiological monitor targeting early 2027 FDA submission; Lucid Diagnostics secured its first lab benefit manager coverage for the EsoGuard test and reported $1.5 million revenue from 2,770 tests; and PAVmed's medical device portfolio, including PortIO and Octeris, reached key development milestones. The company posted a GAAP net loss of $5.5 million but improved cash position to $3.8 million. Upcoming plans include FDA pre-submission meetings and clinical validation studies, supporting PAVmed's growth in medical technology and diagnostics.
At the 2026 Chery International User Summit, Chery introduced its Super Intelligent Valet Parking (SIVP) system, designed to simplify parking for families. The system uses advanced sensors and AI to enable features like One Tap Departure and One Step...
This week saw the debut of one biotech IPO, Lycia Therapeutics, which priced its upsized offering at the top of the range. Additionally, four companies filed initial IPO documents, including two significant biotech firms. Investors are closely watchi...
Cysic plans to burn 7.2 million of its tokens from the foundation reserve to counteract unauthorized creation of 10 million CYS tokens on the BNB Chain during a security breach on October 17. The breach involved the Cysic bridge, which transfers toke...
Bitcoin currently has no agreed-upon upgrade to protect against quantum computing threats. Proposals like BIP-360 and the SHRINCS signature draft aim to enhance cryptographic security but remain in draft form without adoption. BIP-360 would reduce pu...
On October 23, U.S. Bitcoin ETFs experienced net withdrawals of 6,998 BTC, while Ether ETFs lost 19,381 ETH, marking negative flows for both on that day. However, over the past seven days, Bitcoin ETFs still recorded net inflows totaling 4,312 BTC, c...
